Catch up on missed sessions or revisit past presentations. All Journal Club recordings are available in the Course Materials section. Once registered, you can access the recordings, presentations, and article links on the Journal Club page.
Catch up on missed sessions or revisit past presentations. All Journal Club recordings are available in the Course Materials section. Once registered, you can access the recordings, presentations, and article links on the Journal Club page.
Stimulant medications dexamphetamine and methylphenidate appear comparable in short-term symptom response and 12-month persistence after initial randomised allocation, but dexamphetamine may be associated with greater weight loss.
No summary available
No summary available
The Congressional Psychedelics Advancing Therapies Caucus released a report today outlining recommendations for integrating psychedelic-assisted therapy — a combination of psychiatric counseling with controlled doses of psychedelic drugs such as psilocybin or MDMA, also known as ecstasy or molly, to treat mental illnesses — into the nation’s health care system.
No summary available
No summary available
The FDA cleared Motivista, a prescription digital therapeutic, to treat negative symptoms of schizophrenia in adults in conjunction with clinician-managed outpatient care. The authorization was supported by results from the Phase 3 CONVOKE trial, in which patients using Motivista showed significantly greater improvement in negative symptoms than those using a control app, with strong user engagement and no serious treatment-related adverse events reported.
Targeted interventions to address withdrawal, side effects, dependence fears, and housing barriers may boost uptake of ED buprenorphine, a study of adults with opioid use disorder suggested.
The guidelines address the sharp rise in obesity among children and adolescents, setting out how health systems and health workers can deliver timely, evidence-based and people-centered care.
Genome-wide association studies and polygenic risk scores have identified multiple gene loci and variants contributing to the susceptibility to TUD.
Specific gambling behaviors increase risk of problem gambling for SUD patients. SUD treatment programs should screen for and address problem gambling.
Researchers examined cohorts over time to evaluate trends in withdrawal management after the emergence of medetomidine in the unregulated drug supply.
The opioid lawsuits are expected to provide over $50 billion over two decades.
Creating partnerships with community organizations, leadership from an ED champion, and pairing implementation with education for ED staff are key for programmatic success.
The findings suggest higher-intensity interventions are needed to maintain smoke-free homes and support smoking cessation in permanent supportive housing.
Cannabis use screening, cannabis use disorder treatment, and additional intervention to prevent worsening severity are needed to minimize cannabis-related harms among older US adults.
No summary available
This toolkit includes four tools and templates designed to help states and community partners assess existing relationships, identify opportunities for increased coordination, and strengthen cross-sector collaborations across aging, disability, health, and housing systems.
In this sample, ADHD was associated with increased risk for SUDs and earlier onset of substance use.
Exposure to alcohol-related user-generated content on social media and engagement with self-generated content appear to be associated with alcohol use among young people, with largely consistent findings observed across studies.
Cannabis use was associated with a greater odds of signs of sleep-disordered breathing.
Cannabis is used for symptom relief by patients with cyclic vomiting syndrome (CVS). Chronic heavy cannabis use is associated with cannabinoid hyperemesis syndrome (CHS), a condition characterized by recurrent severe nausea, vomiting, and abdominal pain, and considered a subset of CVS.
Among adolescents in Northern California, USA, trends in incident cannabis use disorder rates appeared to increase following recreational cannabis legalization passage, with increasing rates persisting through retail implementation and three years post-passage.
Findings suggest an important population-level benefit of MOUD that may vary according to the prevalence of OUD and the medication type.